Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06165185
Other study ID # 2010_740
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2011
Est. completion date December 31, 2016

Study information

Verified date November 2023
Source Region Skane
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

39 healthy subjects without medication (except oral contraceptives) aged 20-70 years are recruited via advertisements or through telephone contacts with individuals that had previously participated in population-based cohort studies in Malmö. All subjects are exposed to three different intervention procedures; water and coffee loads (acutely and chronically), or no change from usual fluid intake (as a time-control), respectively in randomized order. The daily intake of coffee or water will amount to 3 L of water and 1 L of coffee, respectively for one week each. The three interventions (water, coffee and control), are separated by three weeks of normal fluid intake as a wash-out period. By testing if simple life style interventions, i.e., increased water or coffee intake, may affect vasopressin secretion, evaluated as copeptin, we will increase the knowledge as to whether such life style induced changes of copeptin may in turn lead to effects on glucose tolerance as well as on other cardiometabolic risk factors previously shown to be associated with high copeptin level. Thus, the study will lead to further understanding about vasopressin and copeptin release and how life style manipulation of the vasopressin system may influence glucose metabolism and other cardiometabolic risk factors in healthy individuals.


Description:

Day 1: The initial examination consists of medical history, clinical examination including office blood pressure, and blood sampling (overnight fasting plasma copeptin (a marker of vasopressin), osmolality, insulin, glucagon, glucose, creatinine, hsCRP and OGTT), and start of 24-h urine collection and 24-h ambulatory blood pressure measurement. Day 2: After completion of the 24-h urine collection and ABPM, in the fasting state in the morning, office blood pressure will be measured and blood sampling for plasma copeptin, osmolality insulin, glucagon, glucose, creatinine and hsCRP measurement will be performed. Then, during a maximum time period of 20 minutes, subjects will ingest either 1L of water or 4 dL of coffee, or just 10 ml of water (time control). To map the acute coffee or water effect on copeptin, the experiment proceeds with repeated blood sampling every 30 minutes for 4 hours after the first coffee or water intake. Day 1 then continues with the rest of the daily intake, i.e., 2 L of water or 6 dL of coffee in addition to normal food and fluid intakes. Day 3 to 7: 3 L water per day or 1 L of coffee per day are ingested (or nothing, in the control intervention) in addition to each subject's own food and fluid intake. On days 4 and 6, blood sampling for electrolyte and urea measurement and osmolality will be carried out for reasons of safety and compliance check. Day 8: Fasting in the morning, office blood pressure, blood sampling (copeptin, osmolality, insulin, glucagon, glucose, creatinine, hsCRP) will be performed and a 24-h urine collection and ABPM will be started. Day 9: The final examination will consist of clinical examination including office blood pressure and blood sampling (overnight fasting plasma copeptin, osmolality, insulin, glucagon, glucose, creatinine, hsCRP and OGTT), and end of 24-h urine collection and ABPM.


Recruitment information / eligibility

Status Completed
Enrollment 39
Est. completion date December 31, 2016
Est. primary completion date January 31, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 70 Years
Eligibility Inclusion Criteria: Healthy subjects Age 20-70 years Exclusion Criteria: medication (except oral contraceptives) any type of acute illness any type of chronic illness

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Water
Please see the associated arm description
Coffee
Please see the associated arm description
Control
Please see the associated arm description

Locations

Country Name City State
Sweden Clinical research unit, Internal medicine department, Skåne University Hospital in Malmö Malmö

Sponsors (1)

Lead Sponsor Collaborator
Region Skane

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary 1 week result on plasma copeptin Change ("?-value") between plasma copeptin value (pmol/L) at end of control week and post-intervention values will be calculated.
Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions.
7 days
Secondary 1 week result on plasma glucose Change ("?-value") between plasma glucose (mmol/L) at end of control week and post-intervention values will be calculated.
Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions.
7 days
Secondary 1 week result on plasma insulin Change ("?-value") between plasma insulin (IE) at end of control week and post-intervention values will be calculated.
Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions.
7 days
Secondary 1 week result on plasma glucagon Change ("?-value") between plasma glucagon (pmol/L) at end of control week and post-intervention values will be calculated.
Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions.
7 days
Secondary 1 week result on plasma C-reactive protein Change ("?-value") between plasma C-reactive protein (mg/L) at end of control week and post-intervention values will be calculated.
Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions.
7 days
Secondary 1 week result on plasma creatinine Change ("?-value") between plasma creatinine (umol/L) at end of control week and post-intervention values will be calculated.
Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions.
7 days
Secondary 1 week result on plasma osmolality Change ("?-value") between plasma osmolality (mosm/kg H2O) at end of control week and post-intervention values will be calculated.
Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions.
7 days
Secondary 1 week result on urine osmolality Change ("?-value") between urine osmolality (mosm/kg H2O) at end of control week and post-intervention values will be calculated.
Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions.
7 days
Secondary 1 week result on blood pressure Change ("?-value") between blood pressure (mmHg) at end of control week and post-intervention values will be calculated.
Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions.
7 days
Secondary Acute 4-hour effect of intervention on copeptin To test the hypothesis that acute coffee or water load affects plasma copeptin levels (pmol/L), we will perform paired t-tests (or Wilcoxon's paired rank test in case of no normal distribution) between individual 0 min values (immediately before acute load) and repeated post load values taken each 30 min during 4 hours. 4 hours
See also
  Status Clinical Trial Phase
Completed NCT01587911 - Casinomacropeptide and Satiety N/A